Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke.

Abstract:

:Stroke is the third leading cause of mortality in the USA and one of the leading causes of severe morbidity. It is important to provide stroke patients and physicians with the most accurate prognostic information to optimize care and allocation of healthcare resources. Reliable prognostic markers available during the initial phase after acute stroke may aid clinical decision-making. Several interesting candidate biomarkers have been studied to address prognostic questions; this article will focus on selected inflammatory and neuroendocrine markers. The utility of a biomarker is defined by its ability to improve clinical decision-making and add timely information beyond that readily available from clinical examination and routine imaging. This aim has not been completely achieved yet for any biomarkers, but promising data are available and further studies are ongoing.

journal_name

Expert Rev Neurother

authors

Katan M,Elkind MS

doi

10.1586/ern.10.200

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

225-39

issue

2

eissn

1473-7175

issn

1744-8360

journal_volume

11

pub_type

杂志文章,评审
  • Therapeutic options for cervicogenic headache.

    abstract::The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.863710

    authors: Fernández-de-las-Peñas C,Cuadrado ML

    更新日期:2014-01-01 00:00:00

  • Metabolic treatments of migraine.

    abstract::Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may no...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1729130

    authors: Lisicki M,Schoenen J

    更新日期:2020-03-01 00:00:00

  • New-onset epilepsy: considerations for initial and follow-up MRI to detect brain tumor.

    abstract::Seizures are often the presenting symptoms of a cerebral tumor and may precede its diagnosis by many years. The article under evaluation searched two large English registries for patients admitted for new-onset epilepsy. The risk of subsequently being diagnosed with a malignant brain tumor was found to be 26-fold high...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.80

    authors: Schucht P,Duffau H

    更新日期:2011-08-01 00:00:00

  • Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.

    abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.988709

    authors: Prakash A,Kalra J,Mani V,Ramasamy K,Majeed AB

    更新日期:2015-01-01 00:00:00

  • Role of homocysteine in the treatment of Parkinson's disease.

    abstract::The saga of harmful administration of levodopa (LD) in the treatment of Parkinson's disease (PD) resulted from outcomes of animal trials and cell culture studies. They were initiated after the clinical observation of onset of motor complications related to the short plasma half-life of the drug in PD patients. This di...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.6.957

    authors: Müller T

    更新日期:2008-06-01 00:00:00

  • Chemotherapy for malignant glioma.

    abstract::Malignant gliomas comprise a small percentage of all cancers, but continue to cause disproportionate levels of morbidity and mortality. Despite decades of intensive effort from many disciplines--surgery, radiation oncology and medicine--they remain refractory to cure and, in most cases, even to prolonged treatment res...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.S41

    authors: Nicholas MK,Lukas R,Bangalore S

    更新日期:2005-11-01 00:00:00

  • Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.

    abstract::Guillain-Barré syndrome (GBS) includes demyelinating and axonal subtypes with different immunopathologic mechanisms. In acute inflammatory demyelinating polyradiculoneuropathy, segmental demyelination and conduction block are the pathological and electrophysiological correlates of muscle weakness. Slowed conductions a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.43

    authors: Uncini A,Yuki N

    更新日期:2009-06-01 00:00:00

  • Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

    abstract::Glatiramer acetate (GA; Copaxone(®), Teva Pharmaceuticals Inc.), approved in the USA in 1996 and EU in 2001 as first-line treatment for relapsing-remitting multiple sclerosis, is now available in 51 countries and recently gained approval for delaying conversion to clinically definite multiple sclerosis in patients wit...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.25

    authors: Johnson KP

    更新日期:2012-04-01 00:00:00

  • The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials.

    abstract::The prevalence rate of chronic pain is 15% to 25% in adults while the therapeutic arsenal is still insufficient, especially in relieving neuropathic pain. Peripheral pain transmission is conducted by the small Aδ and C sensory nerve fibres. They express elements from the renin-angiotensin-aldosterone system (RAAS), a ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2016.1150179

    authors: Bessaguet F,Magy L,Desmoulière A,Demiot C

    更新日期:2016-01-01 00:00:00

  • Anaplastic glioma: current treatment and management.

    abstract::Anaplastic glioma (AG) is divided into three morphology-based groups (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) as well as three molecular groups (glioma-CpG island methylation phenotype [G-CIMP] negative, G-CIMP positive non-1p19q codeleted tumors and G-CIMP positive codeleted...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1042455

    authors: Le Rhun E,Taillibert S,Chamberlain MC

    更新日期:2015-06-01 00:00:00

  • The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.

    abstract:INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2018.1476140

    authors: Creese B,Da Silva MV,Johar I,Ballard C

    更新日期:2018-06-01 00:00:00

  • New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.

    abstract::Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.144

    authors: Akhtar RS,Stern MB

    更新日期:2012-12-01 00:00:00

  • Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

    abstract:INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1326818

    authors: Khan A,Corbett A,Ballard C

    更新日期:2017-07-01 00:00:00

  • New therapeutics in spine metastases.

    abstract::The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.831

    authors: Bilsky MH

    更新日期:2005-11-01 00:00:00

  • Epilepsy in the elderly.

    abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.170

    authors: Johnston A,Smith PE

    更新日期:2010-12-01 00:00:00

  • Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies.

    abstract:INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194203

    authors: Amanatkar HR,Papagiannopoulos B,Grossberg GT

    更新日期:2017-01-01 00:00:00

  • The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.

    abstract::Irreversible disability is the critical long-term consequence of multiple sclerosis (MS). While there are well-established measures for disability in MS, they have limitations that may affect our perception of disease progression either due to the empirical nature of some assessments or the lack of validation with lon...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.869478

    authors: Kieseier BC

    更新日期:2014-01-01 00:00:00

  • Emotional dysregulation in adult ADHD: What is the empirical evidence?

    abstract::Attention deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by symptoms of inattention, hyperactivity and impulsivity. There is an ongoing discussion whether symptoms of emotional dysregulation should be added to the conceptualization of ADHD in order to describe the psychopathology ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.109

    authors: Retz W,Stieglitz RD,Corbisiero S,Retz-Junginger P,Rösler M

    更新日期:2012-10-01 00:00:00

  • Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

    abstract::Evaluation of: Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 7, 796-804 (2008). ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.3.319

    authors: Longbrake EE,Racke MK

    更新日期:2009-03-01 00:00:00

  • The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis.

    abstract::The spectrum of idiopathic inflammatory-demyelinating disorders of the CNS is classified based on clinical symptoms and signs, clinical severity, lesion distribution, neuroimaging features and cerebrospinal fluid characteristics. There is a wide variety of conditions in this broad spectrum. In some cases, the dissemin...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.6

    authors: Idiman E,Ozakbaş S

    更新日期:2011-03-01 00:00:00

  • Progress in imaging the effects of psychosis susceptibility gene variants.

    abstract::Genetic imaging has become an increasingly popular tool that utilizes neuroimaging techniques to investigate the impact of genetic variation on the structure, function and connectivity of the brain. Combining genetic and neuroimaging domains is a promising approach to further the understanding of the neural mechanisms...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.145

    authors: Redpath HL,Lawrie SM,Sprooten E,Whalley HC,McIntosh AM,Hall J

    更新日期:2013-01-01 00:00:00

  • Update on the treatment of vitamin B6 dependent epilepsies.

    abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648212

    authors: Mastrangelo M,Cesario S

    更新日期:2019-11-01 00:00:00

  • CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine.

    abstract::Cortical spreading depression (CSD) has been at the center stage of migraine pathophysiology for approximately six decades. Reanalysis of CSD reveals several major unbridgeable gaps in this experimental neurophysiologic concept for migraine. Key phenotypic and pharmacological features of migraine challenge the assumed...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.103

    authors: Gupta VK

    更新日期:2009-11-01 00:00:00

  • Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.

    abstract::Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migrain...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.41

    authors: Freitag FG

    更新日期:2011-04-01 00:00:00

  • Health economic evaluation: why? When? How?

    abstract::Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.865872

    authors: Kobelt G

    更新日期:2013-12-01 00:00:00

  • The impact of receptor-receptor interactions in heteroreceptor complexes on brain plasticity.

    abstract::Allosteric mechanisms in receptor heteromers markedly increase the repertoire of receptor recognition and signaling. Of high importance is the altered function in the receptor heteromer versus the receptor homomer. Such a change in receptor function is mainly brought about by agonist induced allosteric receptor-recept...

    journal_title:Expert review of neurotherapeutics

    pub_type: 社论

    doi:10.1586/14737175.2014.922878

    authors: Fuxe K,Agnati LF,Borroto-Escuela DO

    更新日期:2014-07-01 00:00:00

  • Recent genetic advances in ADHD and diagnostic and therapeutic prospects.

    abstract::Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.4.453

    authors: Hawi Z,Kirley A,Lowe N,Fitzgerald M,Gill M

    更新日期:2003-07-01 00:00:00

  • Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?

    abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.111

    authors: Dennison L,Moss-Morris R

    更新日期:2010-09-01 00:00:00

  • Blood pressure control and prevention of stroke.

    abstract::Hypertension is an important risk factor for stroke. The latter results in disability and premature death and represents a major public health problem. Various studies have established a strong relationship between increasing blood pressure and stroke risk, as well as clear evidence of a reduction in the incidence of ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.6.2.203

    authors: Karthikeyan VJ,Lip GY

    更新日期:2006-02-01 00:00:00

  • Valdecoxib for the management of chronic and acute pain.

    abstract::Cyclooxygenase-2 specific inhibitors have anti-inflammatory and analgesic properties, and are effective in managing a wide range of chronic and acute painful conditions such as adult rheumatoid arthritis, osteoarthritis, migraine, primary dysmenorrhea and postoperative pain. Valdecoxib, an orally administered cyclooxy...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.1.11

    authors: Joshi GP

    更新日期:2005-01-01 00:00:00